ROMANO KATHRYN 4

What Happened

• Kathryn Romano, Chief Accounting Officer of Krystal Biotech (KRYS), exercised 12,500 stock options at $63.55 each (cost = $794,375) on Feb 9, 2026 (transaction code M). The 12,500 shares from that exercise were sold the same day in multiple open-market trades (transaction code S) for aggregate proceeds of approximately $3,401,705. In addition, Romano made a bona fide gift of 750 shares to a charitable donor-advised fund (transaction code G).

Key Details

• Transaction date: 2026-02-09; Form 4 filed 2026-02-11 (timely filing).
• Exercise: 12,500 shares @ $63.55 (total cost $794,375).
• Sales: 12,500 shares sold across multiple trades at weighted average prices by lot (reported lot prices range roughly $270.01–$277.88); total proceeds ≈ $3.40M.
• Gift: 750 shares donated to a donor-advised fund (bona fide charitable gift).
• Footnotes of note:
  • Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Nov 6, 2025 (plan terminates Aug 31, 2026) — indicates pre-arranged trades.
  • The underlying options vested ratably over a four-year period beginning Feb 28, 2022.
  • Multiple-sale price ranges are reported; the filer will provide per-trade breakdown on request.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context

• This was an option exercise followed by same-day sales under a 10b5-1 plan (M = option exercise; S = sale; G = gift). Exercising options and immediately selling the delivered shares is a common, non-pecuniary way for insiders to realize gains; the charitable gift does not signal trading sentiment. The filing shows execution details and the 10b5-1 plan disclosure, which indicates the trades were pre-planned rather than opportunistic.